amlodipine has been researched along with glyburide in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cho, YS; Hwang, EM; Jung, SY; Lim, SM; Min, SJ; Pae, AN; Park, KD; Viswanath, AN | 1 |
| Backenköhler, U; Dörge, H; Heusch, G; Jalowy, A; Post, H; Schulz, R; Vahlhaus, C | 1 |
| Anvari, M; Khalilzadeh, A; Khalilzadeh, O; Sahebgharani, M; Zarrindast, MR | 1 |
| Chang, SY; Gong, X; Osei-Yeboah, F; Paul, S; Perumalla, SR; Shi, L; Sun, CC; Sun, WJ; Zhou, Q | 1 |
| Abreu-Villela, R; Adler, C; Caraballo, I; Kuentz, M | 1 |
| Bafor, EE; Bolanle, IO; Omogbai, EKI | 1 |
1 review(s) available for amlodipine and glyburide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
16 other study(ies) available for amlodipine and glyburide
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.
Topics: Animals; Computer Simulation; Crystallography, X-Ray; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Mice; Mice, Knockout; Molecular Docking Simulation; Potassium Channels, Tandem Pore Domain | 2016 |
Unique cardioprotective action of the new calcium antagonist mibefradil.
Topics: Amlodipine; Animals; Benzimidazoles; Calcium Channel Blockers; Glyburide; Heart; Heart Rate; Heart Ventricles; Mibefradil; Myocardial Infarction; Pressure; Swine; Tetrahydronaphthalenes; Verapamil | 1999 |
Involvement of amlodipine, diazoxide, and glibenclamide in development of morphine tolerance in mice.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Diazoxide; Drug Tolerance; Glyburide; Hypoglycemic Agents; Injections, Intraperitoneal; Male; Mice; Morphine; Narcotics; Nociceptors; Potassium Channels; Vasodilator Agents | 2008 |
Dependence of tablet brittleness on tensile strength and porosity.
Topics: Amlodipine; Cellulose; Drugs, Chinese Herbal; Glyburide; Ibuprofen; Porosity; Powders; Salvia miltiorrhiza; Sildenafil Citrate; Silicon Dioxide; Stearic Acids; Tablets; Tensile Strength; Theophylline | 2015 |
Electron microscopy/energy dispersive X-ray spectroscopy of drug distribution in solid dispersions and interpretation by multifractal geometry.
Topics: Amlodipine; Crystallography, X-Ray; Dosage Forms; Drug Carriers; Drug Compounding; Felodipine; Fractals; Glyburide; Indomethacin; Methylcellulose; Microscopy, Electron, Scanning; Pharmaceutical Preparations; Powder Diffraction; Solubility; Spectrometry, X-Ray Emission; Technology, Pharmaceutical | 2018 |
Effects of amlodipine and valsartan on glibenclamide-treated streptozotocin-induced diabetic rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progression; Drug Interactions; Glyburide; Hypoglycemic Agents; Male; Rats, Wistar; Risk Assessment; Streptozocin; Time Factors; Valsartan | 2018 |